JP2018521020A5 - - Google Patents

Download PDF

Info

Publication number
JP2018521020A5
JP2018521020A5 JP2017563311A JP2017563311A JP2018521020A5 JP 2018521020 A5 JP2018521020 A5 JP 2018521020A5 JP 2017563311 A JP2017563311 A JP 2017563311A JP 2017563311 A JP2017563311 A JP 2017563311A JP 2018521020 A5 JP2018521020 A5 JP 2018521020A5
Authority
JP
Japan
Prior art keywords
compound
following formula
pharmaceutically acceptable
acceptable salt
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017563311A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018521020A (ja
JP6549735B2 (ja
Filing date
Publication date
Priority claimed from PCT/IB2015/001693 external-priority patent/WO2016198908A1/en
Application filed filed Critical
Priority claimed from PCT/US2016/036283 external-priority patent/WO2016200851A1/en
Publication of JP2018521020A publication Critical patent/JP2018521020A/ja
Publication of JP2018521020A5 publication Critical patent/JP2018521020A5/ja
Application granted granted Critical
Publication of JP6549735B2 publication Critical patent/JP6549735B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017563311A 2015-06-09 2016-06-08 核内受容体調節剤 Expired - Fee Related JP6549735B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
IBPCT/IB2015/001693 2015-06-09
PCT/IB2015/001693 WO2016198908A1 (en) 2015-06-09 2015-06-09 Ror nuclear receptor modulators
US201562257806P 2015-11-20 2015-11-20
US62/257,806 2015-11-20
US201662343905P 2016-06-01 2016-06-01
US62/343,905 2016-06-01
PCT/US2016/036283 WO2016200851A1 (en) 2015-06-09 2016-06-08 Nuclear receptor modulators

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019118167A Division JP2019178159A (ja) 2015-06-09 2019-06-26 核内受容体調節剤

Publications (3)

Publication Number Publication Date
JP2018521020A JP2018521020A (ja) 2018-08-02
JP2018521020A5 true JP2018521020A5 (enExample) 2019-02-28
JP6549735B2 JP6549735B2 (ja) 2019-07-24

Family

ID=56194583

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017563311A Expired - Fee Related JP6549735B2 (ja) 2015-06-09 2016-06-08 核内受容体調節剤
JP2019118167A Ceased JP2019178159A (ja) 2015-06-09 2019-06-26 核内受容体調節剤
JP2020135558A Expired - Fee Related JP6938737B2 (ja) 2015-06-09 2020-08-11 核内受容体調節剤
JP2021140781A Active JP7235816B2 (ja) 2015-06-09 2021-08-31 核内受容体調節剤

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019118167A Ceased JP2019178159A (ja) 2015-06-09 2019-06-26 核内受容体調節剤
JP2020135558A Expired - Fee Related JP6938737B2 (ja) 2015-06-09 2020-08-11 核内受容体調節剤
JP2021140781A Active JP7235816B2 (ja) 2015-06-09 2021-08-31 核内受容体調節剤

Country Status (36)

Country Link
US (4) US10106501B2 (enExample)
EP (2) EP3307734B1 (enExample)
JP (4) JP6549735B2 (enExample)
KR (1) KR20180014433A (enExample)
CN (1) CN107820494B (enExample)
AU (3) AU2016276316B2 (enExample)
BR (1) BR112017026452A2 (enExample)
CA (1) CA2988502A1 (enExample)
CL (1) CL2017003147A1 (enExample)
CO (1) CO2017012594A2 (enExample)
CR (1) CR20170594A (enExample)
CY (1) CY1122495T1 (enExample)
DK (1) DK3307734T3 (enExample)
DO (1) DOP2017000289A (enExample)
EC (1) ECSP18001225A (enExample)
ES (1) ES2774517T3 (enExample)
HR (1) HRP20200064T1 (enExample)
HU (1) HUE047988T2 (enExample)
IL (2) IL256043B (enExample)
LT (1) LT3307734T (enExample)
MA (1) MA51556A (enExample)
MX (2) MX372543B (enExample)
MY (1) MY193715A (enExample)
PE (1) PE20230683A1 (enExample)
PH (1) PH12017502237B1 (enExample)
PL (1) PL3307734T3 (enExample)
PT (1) PT3307734T (enExample)
RS (1) RS59934B1 (enExample)
RU (1) RU2715897C2 (enExample)
SG (1) SG10201911849SA (enExample)
SI (1) SI3307734T1 (enExample)
TW (2) TWI726888B (enExample)
UA (1) UA120651C2 (enExample)
UY (1) UY36716A (enExample)
WO (1) WO2016200851A1 (enExample)
ZA (1) ZA201708285B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6549735B2 (ja) * 2015-06-09 2019-07-24 アッヴィ・インコーポレイテッド 核内受容体調節剤
EA035465B1 (ru) 2015-06-09 2020-06-22 Байер Фарма Акциенгезельшафт 7-замещенные 1-арил-нафтиридин-3-амиды карбоновой кислоты в качестве положительных аллостерических модуляторов мускаринового рецептора m2, способ их получения, их применение для лечения и/или профилактики заболеваний и лекарственное средство, содержащее эти соединения
GB201609601D0 (en) 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds
CA3030204A1 (en) 2016-07-11 2018-01-18 Bayer Pharma Aktiengesellschaft 7-substituted 1-pyridyl-naphthyridine-3-carboxylic acid amides and use thereof
JOP20190045A1 (ar) 2016-09-14 2019-03-14 Bayer Ag مركبات أميد حمض 1- أريل-نفثيريدين-3-كربوكسيليك مستبدلة في الموضع 7 واستخدامها.
CN108689942B (zh) * 2017-04-11 2023-06-09 广东东阳光药业有限公司 含氮双环化合物及其制备方法和用途
US11427596B2 (en) * 2019-07-19 2022-08-30 Indian Institute of Technology Indore Metal-free solvent-free synthesis of fused-pyrido heterocycles and biomedical applications
CN110407863B (zh) * 2019-08-24 2021-08-17 中国科学院兰州化学物理研究所 一种通过转移硼化反应合成烯基硼酸酯类化合物的方法
CN110483561B (zh) * 2019-08-24 2021-07-23 中国科学院兰州化学物理研究所 一种烯基硼酸酯类化合物的合成方法
CN114436833B (zh) * 2021-12-27 2024-12-24 南京红太阳医药研究院有限公司 一种替米沙坦关键中间体4′-溴甲基联苯-2-羧酸酯的制备方法
WO2023232870A1 (en) 2022-05-31 2023-12-07 Immunic Ag Rorg/rorgt modulators for the treatment of virus infections like covid-19
AU2024267864A1 (en) * 2023-05-09 2025-11-06 11949098 Canada Inc. Inverse agonists of rar related orphan receptors (rors)
WO2024254218A2 (en) * 2023-06-05 2024-12-12 The Board Of Regents Of The University Of Texas System Non-peptide small molecule fgf14:nav1.6 channel complex protein-protein interaction modulators
CN117263810B (zh) * 2023-09-19 2026-01-27 上海凌凯科技股份有限公司 还原硝基苯制备苯胺类化合物以及选择性碘代苯胺类化合物的方法
CN119241538A (zh) * 2024-09-30 2025-01-03 陕西科技大学 一类三唑并吡啶结构的化合物、合成方法及其应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8641991A (en) 1990-09-10 1992-03-30 Rhone-Poulenc Rorer International (Holdings) Inc. Substituted bicyclic aryl compounds exhibiting selective leukotriene b4 antagonist activity
US5290798A (en) 1991-09-30 1994-03-01 Merck Frosst Canada, Inc. (hetero-arylmethoxy)indoles as inhibitors of leukotriene biosynthesis
ZA928276B (en) 1991-10-31 1993-05-06 Daiichi Seiyaku Co Aromatic amidine derivates and salts thereof.
JP3457694B2 (ja) 1993-02-04 2003-10-20 第一製薬株式会社 インフルエンザ感染予防・治療薬
US5589482A (en) 1994-12-14 1996-12-31 Pfizer Inc. Benzo-thiophene estrogen agonists to treat prostatic hyperplasia
US6124463A (en) 1998-07-02 2000-09-26 Dupont Pharmaceuticals Benzimidazoles as corticotropin release factor antagonists
CA2430978C (en) 2000-12-28 2012-05-15 Daiichi Pharmaceutical Co., Ltd. Vla-4 inhibitors
US20070129334A1 (en) 2001-10-30 2007-06-07 Conforma Therapeutics Corporation Orally Active Purine-Based Inhibitors of Heat Shock Protein 90
JPWO2003091211A1 (ja) 2002-03-28 2005-09-02 住友製薬株式会社 新規ヘテロアリール化合物
BR0317430A (pt) 2002-12-20 2005-10-25 Pharmacia Corp Compostos inibidores de quinase-2 de proteìna ativada por quinase de proteìna ativada por mitógeno
CA2523743A1 (en) 2003-04-30 2004-11-18 The Institutes For Pharmaceutical Discovery, Llc Heterocycle substituted carboxylic acids as inhibitors of protein tyrosine phosphatase-1b
WO2005012296A1 (en) 2003-07-28 2005-02-10 Janssen Pharmaceutica N.V. Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators
UY28526A1 (es) 2003-09-24 2005-04-29 Boehringer Ingelheim Pharma Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos
US7417063B2 (en) 2004-04-13 2008-08-26 Bristol-Myers Squibb Company Bicyclic heterocycles useful as serine protease inhibitors
US20080269284A1 (en) 2004-06-24 2008-10-30 Eli Lilly And Company Compounds and Methods for Treating Dyslipidemia
WO2006050076A1 (en) 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
WO2006049952A1 (en) 2004-10-29 2006-05-11 Eli Lilly And Company Cycloalkyl lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
MY153898A (en) * 2005-06-22 2015-04-15 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
FR2890071B1 (fr) 2005-08-30 2007-11-09 Fournier Sa Sa Lab Nouveaux composes de l'indole
WO2007108936A2 (en) 2006-03-15 2007-09-27 Wyeth N-substituted-azacyclylamines as histamine-3 antagonists
US8026257B2 (en) 2007-07-11 2011-09-27 Bristol-Myers Squibb Company Substituted heterocyclic ethers and their use in CNS disorders
JP5758630B2 (ja) * 2007-11-15 2015-08-05 エンメエッセディ・イタリア・エッセ・エッレ・エッレ Parp阻害剤としてのピリダジノン誘導体
AU2010210426B2 (en) 2009-02-06 2015-06-11 Imago Pharmaceuticals, Inc. Inhibitors of Jun N-terminal kinase
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
NZ598269A (en) 2009-09-18 2014-12-24 Zalicus Pharmaceuticals Ltd Aryl sulphone derivatives as calcium channel blockers
WO2012068589A2 (en) 2010-11-19 2012-05-24 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
US8466186B2 (en) * 2010-12-10 2013-06-18 Boehringer Ingelheim International Gmbh Compounds
EP2487159A1 (en) * 2011-02-11 2012-08-15 MSD Oss B.V. RorgammaT inhibitors
JP6052685B2 (ja) 2011-07-25 2016-12-27 アラーガン、インコーポレイテッドAllergan,Incorporated α2アドレナリン受容体の調節因子としてのN−(イミダゾリジン−2−イリデン)−ヘテロシクロペンタ[b]ピリジン誘導体
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
UA111754C2 (uk) * 2011-10-06 2016-06-10 Байєр Фарма Акцієнгезелльшафт Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань
KR20140077963A (ko) 2011-10-20 2014-06-24 글락소스미스클라인 엘엘씨 시르투인 조절제로서의 치환된 비시클릭 아자-헤테로사이클 및 유사체
EP2647628A1 (en) 2012-04-02 2013-10-09 Almirall, S.A. Substituted tricyclic compounds with activity towards ep1 receptors
WO2014026328A1 (en) * 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 3-cyclohexenyl substituted indole and indazole compounds as rorgammat inhibitors and uses thereof
EP2991994B1 (en) 2013-05-01 2018-08-15 Vitae Pharmaceuticals, Inc. Thiazolopyrrolidine inhibitors of ror-gamma
CU24398B1 (es) * 2013-08-02 2019-04-04 Pfizer 3-(piperidin,pirrol o azetidin)-indoles sustituidos útiles como inhibidores rorc2
CN105531274A (zh) * 2013-09-11 2016-04-27 豪夫迈·罗氏有限公司 作为RORc调节剂的酮-咪唑并吡啶衍生物
DK3102576T3 (da) 2014-02-03 2019-07-22 Vitae Pharmaceuticals Llc Dihydropyrrolopyridininhibitorer af ror-gamma
SI3207043T1 (sl) 2014-10-14 2019-04-30 Vitae Pharmaceuticals, Inc. Dihidropirolopiridinovi inhibitorji za ROR-gama
JP6549735B2 (ja) * 2015-06-09 2019-07-24 アッヴィ・インコーポレイテッド 核内受容体調節剤

Similar Documents

Publication Publication Date Title
JP2017008120A5 (enExample)
JP2012107057A5 (enExample)
JP2018030858A5 (enExample)
JP2017509667A5 (enExample)
JP2018168171A5 (enExample)
JP2014507446A5 (enExample)
JP2017186358A5 (enExample)
JP2014221779A5 (enExample)
JP2013532687A5 (enExample)
JP2013532130A5 (enExample)
JP2018150298A5 (enExample)
JP2020515557A5 (enExample)
JP2012111758A5 (enExample)
JP2011105738A5 (enExample)
JP2016535100A5 (enExample)
JP2015199738A5 (enExample)
JP2011510079A5 (enExample)
JP2018525542A5 (enExample)
JP2011519871A5 (enExample)
JP2016532632A5 (enExample)
JP2017505336A5 (enExample)
JP2016539168A5 (enExample)
JP2017014205A5 (enExample)
JP2017019744A5 (enExample)
JP2016057150A5 (enExample)